Joyce O'Shaugnessy, MD, Texas Oncology

Articles by Joyce O'Shaugnessy, MD, Texas Oncology

Updated Data for Metastatic HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Prognostic Tools for Early-Stage HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Current Treatment Landscape for HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Latest Updated Articles

Prognostic Tools for Early-Stage HER2+ Breast Cancer
January 25th 2021
Current Treatment Landscape for HER2+ Breast Cancer
January 25th 2021
Updated Data for Metastatic HER2+ Breast Cancer
January 25th 2021

Trending on OncLive

Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

Five Under 5: Top Oncology Videos for the Week of 9/20

FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC

Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma